Therapeutic RNAi agents for treating psoriasis

• US 20060115455A1
• Filed: 10/21/2005
• Published: 06/01/2006
• Est. Priority Date: 10/22/2004
• Status: Abandoned Application

• Current Assignee: Benitec, Inc. (Benitec Biopharma Limited)
• Original Assignee: Benitec, Inc. (Benitec Biopharma Limited)
• Inventors: Brashears, Sarah J., Reed, Kenneth Clifford
• Application Number:
  US11/256,666
• Publication Number:
  US 20060115455A1
• Time in Patent Office: Days
• US Class Current: 424/93.200
• CPC Class Codes: A61L 15/44 Medicaments
• CPC Class Codes: A61L 2300/258 Genetic materials, DNA, RNA, genes, vectors, e.g. plasmids
• CPC Class Codes: A61L 2300/64 Animal cells
• CPC Class Codes: C12N 15/111 General methods applicable to biologically active non-coding nucleic acids
• CPC Class Codes: C12N 15/113 Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing when used in plants C12N15/8218
• CPC Class Codes: C12N 2310/14 interfering N.A.
• CPC Class Codes: C12N 2310/53 partially self-complementary or closed
• CPC Class Codes: C12N 2320/32 Special delivery means, e.g. tissue-specific

Abstract

The present invention provides compositions and methods suitable for delivering RNAi agents against genetic targets in skin tissues so as to treat psoriasis.

Claims

1. A method for treating or preventing psoriasis, said method comprising administering a first RNAi agent to a subject, wherein the first RNAi agent downregulates or silences one or more transcriptionally active genetic regions that are directly or indirectly associated with the onset, development, maintenance, or progression of psoriasis.

2. The method of claim 1, wherein the first RNAi agent comprises a nucleotide sequence that is at least 70% identical to at least a part of a nucleotide sequence comprising a psoriasis associated genetic target.

3. The method of claim 1, wherein the first RNAi agent is a ddRNAi agent.

4. The method of claim 1, wherein the first RNAi agent is formulated with a compress or bandage and is administered to the subject with the compress or bandage.

5. The method of claim 1, wherein the first RNAi agent is reversibly associated with a carrier, coating, or matrix.

6. The method of claim 1, wherein the first RNAi agent is covalently attached to a carrier or coating.

7. The method of claim 1, wherein the first RNAi agent is administered to the subject by a viral delivery system.

8. The method of claim 1, wherein the first RNAi agent downregulates or silences a first transcriptionally active genetic region that is directly or indirectly associated with the onset, development, maintenance, or progression of psoriasis, and further comprising administering to the subject a second RNAi agent that downregulates or silences a second transcriptionally active genetic region that is directly or indirectly associated with the onset, development, maintenance, or progression of psoriasis.

9. A genetically modified cell comprising a ddRNAi expression cassette that expresses a ddRNAi agent that downregulates or silences one or more transcriptionally active genetic regions that are directly or indirectly associated with the onset, development, maintenance, or progression of psoriasis.

10. A therapeutic device comprising an RNAi agent that downregulates or silences one or more transcriptionally active genetic regions that are directly or indirectly associated with the onset, development, maintenance, or progression of psoriasis and a carrier.